|
KMID : 1036020190080010008
|
|
지질.동맥경화학회지
2019 Volume.8 No. 1 p.8 ~ p.14
|
|
|
Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
|
|
Kwak Soon-Gu
Yang Han-Mo
|
|
|
Abstract
|
|
|
|
Choosing antithrombotic regimens for patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI) with stent placement is challenging. Until recently, the guidelines recommended warfarin-based triple therapy, which causes frequent major bleeding events in up to 12% of patients during the first year of treatment. The WOEST trial, however, revealed that dual therapy, by without aspirin, resulted in significantly lower bleeding risks with similar thromboembolic events to triple therapy. Subsequently, efforts to seek the optimal dual therapy regimens, especially with the combination of a non-vitamin K antagonist oral anticoagulant (NOAC), were initiated. This review highlights the evidence for dual therapy using an NOAC for patients with AF who underwent PCI, with an emphasis on reduced bleeding risk.
|
|
|
KEYWORD
|
|
|
Anticoagulants, Atrial fibrillation, Non-vitamin K antagonist oral anticoagulant, Percutaneous coronary intervention
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|
|